Literature DB >> 30184331

Enhancing mechanical properties of an injectable two-solution acrylic bone cement using a difunctional crosslinker.

Michael J Wiegand1,2, Kennedy L Faraci1,2, Brittany E Reed1,2, Julie M Hasenwinkel1,2.   

Abstract

Two-solution bone cements modified with ethylene glycol-dimethacrylate (EG-DMA) as a crosslinker have been developed as an attempt to further improve the mechanical properties of acrylic bone cement. The result of this study shows that EG-DMA can increase the mechanical properties and fractional monomer conversion while preserving the thermal characteristics. The strength and bending modulus increase with EG-DMA concentrations at 5-10 vol % EG-DMA. Substituting the EG-DMA content past 10 vol % decreases the bending properties due to the effects of reduced monomer concentrations. Strengthened EG-DMA samples demonstrated an increase in ductility with noticeably different fracture surface morphologies than the control samples, indicated by microtroughs and ridge formation caused by excessive plastic strain. This work provides insight into the effect of substituting a crosslinker for MMA monomer in an injectable two-solution system and lays out the ideal concentrations of EG-DMA for superior mechanical or fractional monomer conversion properties.
© 2018 Wiley Periodicals, Inc. J. Biomed. Mater. Res. Part B, 2018. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 783-790, 2019. © 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  acrylic; bone cement-PMMA; ethylene glycol-dimethacrylate; fractional conversion; mechanical properties

Mesh:

Substances:

Year:  2018        PMID: 30184331     DOI: 10.1002/jbm.b.34172

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  1 in total

1.  Effect of Physiological Fluids Contamination on Selected Mechanical Properties of Acrylate Bone Cement.

Authors:  Robert Karpiński; Jakub Szabelski; Jacek Maksymiuk
Journal:  Materials (Basel)       Date:  2019-11-29       Impact factor: 3.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.